In June 2019, the companies QPharma AB and Disphar International BV were reorganized. A group was constructed to serve all customers for contract development and manufacturing in the business-to-business segment. Further to the integration, the name of all legal entities in the CDMO group will be changed to Sever Pharma Solutions as of today.
“Using the same company name emphasizes the fact that the group is fully integrated. It also makes it easier to communicate the unique capabilities and expertise that the group can provide. Sever Pharma Solutions is the committed CDMO specialized in enhancing highly potent pharma solutions,” says CEO Kenneth Stokholm.
The company will be able to add value throughout the development and manufacturing processes with expertise in highly potent drugs and polymer-based drug delivery systems, comprehensive material options, and creative solutions.
By providing a complete value chain, Sever Pharma Solutions can offer an optimized end-to-end solution from development through sourcing and worldwide commercial supply.
As a committed long-term partner with a strong focus on creating a commercial product, the company will put all its resources to work for its customers. Sever Pharma Solutions also has global GMP compliance, regulatory services, and market access strategies to ensure that its customers’ products will benefit patients all over the world.
